Claims
- 1. A method of conducting an enantioselective aldol reaction between an aldehyde and a donor molecule selected from a ketone bearing an a-hydrogen and a nitroalkyl compound, the method comprising
contacting said aldehyde and said donor molecule in the presence of a catalytic amount of an asymmetric catalyst, wherein said catalyst is a complex of a Group 2A or Group 2B metal with a chiral ligand of formula I: 132where R1-R4 are aryl groups, which may be the same or different, each of which is unsubstituted or substituted with one or more substituents X, where each X is independently selected from alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, aralkynyl, alkoxy, aryloxy, amide, alkyl- or aryl sulfonyl, sulfonamide, hydroxy, cyano, nitro, and halogen, wherein R1 and R2, or R3 and R4, or both of these combinations, may be linked at an α-carbon of each said group to form a tricyclic or larger ring system; m is an integer from 0 to 3; each of R5 and R6 represents one or more substituents independently selected from the group consisting of hydrogen and X as defined above; and R7 represents one or more substituents on the phenol ring independently selected from the group consisting of hydrogen, X as defined above, and a further fused ring; under conditions effective to produce an aldol reaction product which is enriched in one of the possible stereoisomeric products of such reaction.
- 2. The method of claim 1, wherein the Group 2A or Group 2B metal is selected from the group consisting of Zn, Cd, Mg, Ca, and Ba.
- 3. The method of claim 1, wherein the metal is Zn.
- 4. The method of claim 1, wherein each of R1-R4 is selected from phenyl, α-naphthyl, and β-naphthyl, unsubstituted or substituted with a group selected from X as defined in claim 1.
- 5. The method of claim 4, wherein each of R1-R4 is selected from phenyl, α-naphthyl, and β-naphthyl, unsubstituted or substituted with a group selected from lower alkyl, lower alkoxy, and halogen.
- 6. The method of claim 1, wherein m is 1.
- 7. The method of claim 6, wherein each of R and R is hydrogen.
- 8. The method of claim 1, wherein each Re is independently selected from hydrogen, lower alkyl, lower alkoxy, and halogen.
- 9. The method of claim 1, wherein the ketone is an aryl methyl ketone or an aryl (hydroxymethyl) ketone.
- 10. The method of claim 1, wherein the donor compound and aldehyde are present in a molar ratio between about 1:1 and 10:1.
- 11. The method of claim 1, wherein the amount of catalyst is about 2.5 to 10 mole percent, relative to moles of aldehyde.
- 12. A catalytic composition consisting of a complex of a Group 2A or Group 2B metal with a chiral ligand of formula I
- 13. The composition of claim 12, wherein the Group 2A or Group 2B metal is selected from the group consisting of Zn, Cd, Mg, Ca, and Ba.
- 14. The composition of claim 13, wherein the metal is Zn.
- 15. The composition of claim 12, wherein each of R1-R4 is phenyl, a-naphthyl, or β-naphthyl, unsubstituted or substituted with a group selected from X as defined in claim 12.
- 16. The composition of claim 15, wherein each of R1-R4 is phenyl, α-naphthyl, or P-naphthyl, unsubstituted or substituted with a group selected from lower alkyl, lower alkoxy, and halogen.
- 17. The composition of claim 12, wherein m is 1.
- 18. The composition of claim 17, wherein each of R5 and R6 is hydrogen.
- 19. The composition of claim 12, wherein each R7 is independentyl selected from hydrogen, lower alkyl, lower alkoxy, and halogen.
- 20. The composition of claim 12, wherein said chiral ligand is selected from the group consisting of ligands 1a-1n as disclosed herein.
- 21. The composition of claim 20, wherein said chiral ligand is selected from the group consisting of ligands 1a, 1c-d, and 1 m as disclosed herein.
- 22. A catalytic composition formed by contacting a chiral ligand of formula I:
- 23. The composition of claim 22, wherein said Group 2A or Group 2B metal compound is a dialkyl metal, dialkoxy metal, alkyl metal halide, alkyl (dialkylamino) metal or alkyl (diarylamino) metal.
- 24. The composition of claim 22, wherein the Group 2A or Group 2B metal is selected from the group consisting of Zn, Cd, Mg, Ca, and Ba.
- 25. The composition of claim 24, wherein the metal is Zn.
- 26. The composition of claim 25, wherein said metal compound is a di(lower alkyl) zinc compound.
- 27. The composition of claim 22, wherein each of R1-R4 is phenyl, a-naphthyl, or β-naphthyl, unsubstituted or substituted with a group selected from X as defined in claim 22.
- 28. The composition of claim 22, wherein each of R1-R4 is phenyl, a-naphthyl, or β-naphthyl, unsubstituted or substituted with a group selected from lower alkyl, lower alkoxy, and halogen.
- 29. The composition of claim 22, wherein m is 1.
- 30. The composition of claim 29, wherein each of R5 and R6 is hydrogen.
- 31. The composition of claim 22, wherein each R7 is independentyl selected from hydrogen, lower alkyl, lower alkoxy, and halogen.
- 32. The composition of claim 22, wherein said chiral ligand is selected from the group consisting of ligands 1a-1n as disclosed herein
- 33. The composition of claim 32, wherein said chiral ligand is selected from the group consisting of ligands 1a, 1c-d, and 1 m as disclosed herein.
- 34. A chiral ligand of formula I:
- 35. The ligand of claim 34, wherein each of R1-R4 is phenyl x-naphthyl, or naphthyl, unsubstituted or substituted with a group selected from X as defined in claim 34.
- 36. The ligand of claim 35, wherein each of R1-R4 is phenyl α-naphthyl, or naphthyl, unsubstituted or substituted with a group selected from lower alkyl, lower alkoxy, and halogen.
- 37. The ligand of claim 34, wherein m is 1.
- 38. The ligand of claim 37, wherein each of R5 and R6 is hydrogen.
- 39. The ligand of claim 34, wherein each R7 is independentyl selected from hydrogen, lower alkyl, lower alkoxy, and halogen.
- 40. The ligand of claim 34, selected from the group consisting of ligands 1a-1n as disclosed herein.
- 41. The ligand of claim 40, selected from the group consisting of ligands 1a, 1c-d, and 1m as disclosed herein.
Parent Case Info
[0001] This application claims priority to U.S. provisional application serial No. 60/244,833, filed Nov. 1, 2000, which is hereby incorporated by reference in its entirety.
[0002] This invention was made with the support of the National Science Foundation and the National Institutes of Health, General Medical Sciences. Accordingly, the U.S. Government may have certain rights in this invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60244833 |
Nov 2000 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09999802 |
Oct 2001 |
US |
Child |
10452082 |
May 2003 |
US |